Inhibikase Therapeutics, Inc.
IKTHealthcare|Biotechnology|US
$1.50
+0.06 (+4.17%)
DCF Value
$1.41
Tangible Book / Share
$0.88
Cash / Share
$0.91
Financials
Financial Snapshot
Market Cap
$209.3M
Enterprise Value
$178.1M
Revenue (TTM)
$0.00
Net Income (TTM)
-$60.6M
Cash & Investments
$159.0M
Net Cash
$159.0M
Free Cash Flow (TTM)
-$43.1M
Operating CF (TTM)
-$42.6M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$159.0M
Quarterly Burn
$10.7M
Monthly Burn
$3.6M
Est. Runway
~14.9 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $12.0K | $16.7K | $379.6K | $18.5K | $14.0M | $40.8M | $23.1M | $13.3M | $97.5M | $178.8M | $159.0M | |
| Operating Cash Flow | -$29.6K | -$126.4K | $715.0K | -$338.3K | -$1.1M | -$14.3M | -$17.4M | -$18.1M | -$19.1M | -$27.8M | -$42.6M | |
| Free Cash Flow | -$29.6K | -$126.4K | $715.0K | -$338.3K | -$1.1M | -$14.3M | -$17.6M | -$18.1M | -$19.1M | -$27.8M | -$43.1M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.00 | -$243.3K | -$14.2K | $0.00 | -$13.4K | -$452.0K | |
| Financing Cash Flow | -$23.8K | $131.0K | -$439.2K | -$22.8K | $15.1M | $41.1M | -$204.8K | $8.4M | $103.5M | $108.5M | $111.3M |
R&D Spending
R&D (TTM)
$38.2M
R&D Intensity
—
R&D Growth vs Prior
+28.4%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $967.4K | $2.1M | $4.0M | $1.1M | $698.5K | $3.1M | $123.4K | $260.5K | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $846.4K | $1.8M | $3.6M | $2.6M | $893.8K | $11.4M | $12.0M | $13.6M | $17.2M | $29.8M | $38.2M | |
| R&D % of Revenue | 87.5% | 85.2% | 90.3% | 227.4% | 128.0% | 366.4% | 9749.7% | 5227.8% | — | — | — | |
| SG&A | $734.3K | $710.4K | $2.5M | $0.00 | $0.00 | $0.00 | $6.2M | $6.7M | $11.4M | $23.6M | $27.4M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $967.4K | $2.1M | $4.0M | $1.1M | $698.5K | $3.1M | $123.4K | $260.5K | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $846.4K | $1.8M | $3.6M | $2.6M | $893.8K | $11.4M | $6.7K | $13.6M | $26.3K | $0.00 | $0.00 | |
| Gross Profit | $121.0K | $305.2K | $393.8K | -$1.4M | -$195.3K | -$8.3M | $116.7K | -$13.4M | -$26.3K | $0.00 | $0.00 | |
| R&D | $846.4K | $1.8M | $3.6M | $2.6M | $893.8K | $11.4M | $12.0M | $13.6M | $17.2M | $29.8M | $38.2M | |
| SG&A | $734.3K | $710.4K | $2.5M | $0.00 | $0.00 | $0.00 | $6.2M | $6.7M | $11.4M | $23.6M | $27.4M | |
| Operating Income | -$613.3K | -$405.1K | -$2.1M | -$5.7M | -$2.8M | -$14.8M | -$18.1M | -$20.1M | -$28.6M | -$52.0M | -$65.8M | |
| Interest Expense | $0.00 | $0.00 | $30.3K | $24.8K | $29.4K | $19.9K | $74.5K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$628.7K | -$436.1K | -$2.2M | -$5.7M | -$2.8M | -$14.8M | -$18.1M | -$19.0M | -$27.5M | -$48.3M | -$60.6M | |
| Net Income | -$628.7K | -$436.1K | -$2.2M | -$5.7M | -$2.8M | -$14.8M | -$18.1M | -$19.0M | -$27.5M | -$48.3M | -$60.6M | |
| EPS (Diluted) | -0.48 | -0.25 | -1.61 | -3.34 | -1.72 | -4.88 | -4.26 | -3.57 | -1.16 | -0.49 | -0.48 | |
| EBITDA | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$18.0M | -$18.9M | -$27.5M | -$53.3M | -$62.3M | |
| Shares Out. (M) | 1.30 | 1.72 | 1.34 | 1.72 | 1.68 | 3.03 | 4.20 | 5.33 | 23.71 | 98.31 | 174.57 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.0K | $16.7K | $379.6K | $18.5K | $14.0M | $40.8M | $7.2M | $9.2M | $56.5M | $139.2M | $31.2M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $15.9M | $4.1M | $41.1M | $39.5M | $127.8M | |
| Total Current Assets | $80.2K | $198.1K | $1.3M | $35.4K | $14.8M | $42.5M | $24.4M | $14.2M | $98.5M | $180.1M | $162.3M | |
| Total Assets | $162.9K | $285.2K | $2.8M | $38.3K | $14.8M | $42.5M | $24.9M | $14.5M | $98.6M | $181.2M | $163.6M | |
| Total Current Liabilities | $1.5M | $1.7M | $3.6M | $4.3M | $4.7M | $4.1M | $3.7M | $3.4M | $3.7M | $8.3M | $10.3M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $275.4K | $276.5K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $1.5M | $1.7M | $3.6M | $4.5M | $5.0M | $4.1M | $3.9M | $3.5M | $3.7M | $8.3M | $10.3M | |
| Stockholders' Equity | -$1.4M | -$1.4M | -$778.0K | -$4.5M | $9.8M | $38.4M | $21.0M | $11.0M | $94.9M | $172.9M | $153.3M | |
| Retained Earnings | -$3.9M | -$4.3M | -$6.5M | -$12.2M | -$15.0M | -$29.8M | -$47.9M | -$66.9M | -$94.4M | -$142.7M | -$178.7M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$29.6K | -$126.4K | $715.0K | -$338.3K | -$1.1M | -$14.3M | -$17.4M | -$18.1M | -$19.1M | -$27.8M | -$42.6M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.00 | -$243.3K | -$14.2K | $0.00 | -$13.4K | -$452.0K | |
| Free Cash Flow | -$29.6K | -$126.4K | $715.0K | -$338.3K | -$1.1M | -$14.3M | -$17.6M | -$18.1M | -$19.1M | -$27.8M | -$43.1M | |
| Investing Cash Flow | $0.00 | $0.00 | $87.1K | $0.00 | $0.00 | $0.00 | -$16.0M | $11.7M | -$37.0M | $2.1M | -$115.2M | |
| Financing Cash Flow | -$23.8K | $131.0K | -$439.2K | -$22.8K | $15.1M | $41.1M | -$204.8K | $8.4M | $103.5M | $108.5M | $111.3M | |
| Issuance of Stock | $0.00 | $0.00 | $1.2M | $0.00 | $14.8M | $41.1M | $44.1K | $8.5M | $103.5M | $108.5M | $111.3M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | -$26.3K | -$22.8K | $272.8K | -$42.5K | -$248.9K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $310.1K | $300.7K | $642.2K | $1.4M | $573.7K | $1.5M | $458.1K | $500.1K | $8.1M | $15.3M | $20.0M | |
| Net Change in Cash | -$53.3K | $4.6K | $362.9K | -$361.1K | $13.9M | $26.8M | -$33.6M | $2.0M | $47.3M | $82.7M | -$46.5M |
Dilution Tracker
Shares outstanding grew 5768.8% over 5 years — significant dilution
Shares Outstanding
140M
5-Year Share Growth
+5768.8%
Stock Issuance (TTM)
$111.3M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 1.30 | 1.72 | 1.34 | 1.72 | 1.68 | 3.03 | 4.20 | 5.33 | 23.71 | 98.31 | 174.57 | |
| Change vs Prior % | — | 32.4% | -22.4% | 28.8% | -2.6% | 81.2% | 38.5% | 26.9% | 344.6% | 314.6% | 77.6% | |
| Stock Issuance | $0.00 | $0.00 | $1.2M | $0.00 | $14.8M | $41.1M | $44.1K | $8.5M | $103.5M | $108.5M | $111.3M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $310.1K | $300.7K | $642.2K | $1.4M | $573.7K | $1.5M | $458.1K | $500.1K | $8.1M | $15.3M | $20.0M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 12.5% | 14.8% | 9.7% | -127.4% | -28.0% | -266.4% | 94.6% | -5127.8% | — | — | — | |
| Operating Margin % | -63.4% | -19.7% | -52.5% | -507.5% | -403.5% | -476.2% | -14686.2% | -7712.0% | — | — | — | |
| Net Margin % | -65.0% | -21.2% | -53.3% | -509.7% | -407.7% | -476.9% | -14625.9% | -7304.8% | — | — | — | |
| EBITDA Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -14620.4% | -7236.7% | — | — | — | |
| FCF Margin % | -3.1% | -6.1% | 17.7% | -30.1% | -161.7% | -461.1% | -14253.4% | -6947.9% | — | — | — | |
| ROE % | 46.5% | 30.3% | 276.7% | 127.5% | -29.1% | -38.5% | -85.8% | -173.3% | -29.0% | -27.9% | -42.8% | |
| ROA % | -385.9% | -152.9% | -75.6% | -14960.5% | -19.3% | -34.8% | -72.4% | -131.2% | -27.9% | -26.6% | -37.1% | |
| ROIC % | 60.0% | 41.3% | 389.9% | 138.4% | -27.9% | -38.2% | -84.8% | -173.2% | -30.1% | -30.1% | -42.9% | |
| R&D / Revenue % | 87.5% | 85.2% | 90.3% | 227.4% | 128.0% | 366.4% | 9749.7% | 5227.8% | — | — | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 113.0% | 96.1% | -72.2% | -37.8% | 343.9% | -96.0% | 111.0% | -100.0% | 0.0% | |
| Gross Profit | 0.0% | 152.3% | 29.0% | -463.1% | 86.3% | -4127.9% | 101.4% | -11544.6% | 99.8% | 100.0% | |
| Operating Income | 0.0% | 33.9% | -423.8% | -168.5% | 50.5% | -423.9% | -22.8% | -10.8% | -42.3% | -81.8% | |
| Net Income | 0.0% | 30.6% | -393.6% | -165.9% | 50.2% | -419.2% | -22.1% | -5.4% | -44.6% | -75.4% | |
| EPS (Diluted) | 0.0% | 47.9% | -544.0% | -107.5% | 48.5% | -183.7% | 12.7% | 16.2% | 67.5% | 57.8% | |
| Operating Cash Flow | 0.0% | -327.4% | 665.7% | -147.3% | -233.8% | -1165.9% | -21.4% | -4.2% | -5.9% | -45.1% | |
| Free Cash Flow | 0.0% | -327.4% | 665.7% | -147.3% | -233.8% | -1165.9% | -23.1% | -2.9% | -5.8% | -45.1% | |
| R&D Expense | 0.0% | 107.4% | 107.7% | -30.0% | -65.0% | 1170.9% | 6.0% | 13.2% | 26.4% | 73.1% | |
| SG&A Expense | 0.0% | -3.3% | 254.2% | -100.0% | 0.0% | 0.0% | 0.0% | 8.4% | 69.0% | 107.0% | |
| Total Assets | 0.0% | 75.0% | 898.2% | -98.7% | 38543.6% | 187.3% | -41.3% | -41.8% | 579.7% | 83.8% | |
| Book Value / Share | 0.0% | 19.5% | 30.5% | -348.1% | 323.8% | 116.7% | -60.5% | -58.9% | 94.4% | -56.0% | |
| Debt | 0.0% | 39.8% | -49.2% | 59.9% | -14.7% | -22.0% | 41.1% | 77.1% | -82.2% | -100.0% | |
| Diluted Shares | 0.0% | 32.4% | -22.4% | 28.8% | -2.6% | 81.2% | 38.5% | 26.9% | 344.6% | 314.6% |
Valuation
P/E (TTM)At Loss
P/S0.00
10Y Low / Med / High8.63 / 79.79 / 102.12
P/B1.71
10Y Low / Med / High0.60 / 0.81 / 7.09
EV/EBITDAAt Loss
EV/Revenue0.00
10Y Low / Med / High19.60 / 79.77 / 91.32
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$1.41
Tangible Book / Share
$0.88
Net Current Assets / Share
$1.09
Graham Net-Net
$0.85
Cash / Share
$0.91
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -123.75 | -237.60 | -36.89 | -17.78 | -24.07 | -1.81 | -0.70 | -0.36 | -2.80 | -4.18 | -3.16 | |
| P/S Ratio | 79.79 | 49.58 | 19.63 | 91.01 | 99.29 | 8.63 | 102.12 | 26.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -57.11 | -70.91 | -101.98 | -22.76 | 7.09 | 0.70 | 0.60 | 0.62 | 0.81 | 1.17 | 1.71 | |
| EV/EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.32 | 0.09 | -0.75 | -1.17 | -2.86 | |
| EV/Revenue | 80.12 | 49.79 | 19.60 | 91.32 | 79.77 | -4.43 | 46.73 | -6.80 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
10.57
Safe
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $285.7K | $400.0K | $36.7M |
| Net Income | -$42.7M | -$43.6M | -$38.8M |
| EPS | $-0.43 | $-0.46 | $-0.40 |
| # Analysts (EPS) | 6 | 6 | 5 |